CARTAGENA PROTOCOL ON BIOSAFETY TO THE CONVENTION ON BIOLOGICAL DIVERSITY — Rwanda law | Esheria

CARTAGENA PROTOCOL ON BIOSAFETY TO THE CONVENTION ON BIOLOGICAL DIVERSITY

The provision states the objective of the protocol: to help ensure an adequate level of protection for the safe transfer, handling, and use of living modified organisms, especially for transboundary movements.

AI-assisted research synopsis — verify against the official legal text below.

Jurisdiction
Rwanda
Instrument
Act or statute
Status
In force
Version
Undated source snapshot
Language
mul
Updated
Official source
View official record ↗
biodiversity biological diversity biological resources biosafety biotechnology budgetary arrangements capacity building commercial use restrictions competent authority designation compliance controls compliance procedures compliance reporting conference procedures contained use cross-border movement cross-border movement controls cross-border notification cross-border transfer decision review deposit of treaty text disclosure control document authenticity documentation emergency notification +44 more

Statute overview

About this statute

The provision states the objective of the protocol: to help ensure an adequate level of protection for the safe transfer, handling, and use of living modified organisms, especially for transboundary movements. Each Party must take the legal and administrative measures needed to implement the Protocol, and Parties must manage living modified organisms to reduce risks to biodiversity and human health. This article defines key terms used in the Protocol, including export, import, living modified organism, and transboundary movement. This article says the protocol applies to transboundary movement, transit, handling, and use of living modified organisms, but the advance informed agreement procedure does not apply to organisms in transit or to certain organisms destined for contained use under the import party’s standards. This provision says the Protocol does not apply to transboundary movements of human pharmaceuticals made from living modified organisms when they are covered by other relevant international agreements or organisations.